I think Pfizer is in a better position than meets the eye to navigate its patent cliff. The company has several new products with strong growth prospects, notably including migraine drug Nurtec ODT, RSV vaccine Abrysvo, and multiple myeloma drug Elrexfio. Pfizer's pipeline also features 108 candidates, with 28 late-stage programs and four awaiting regulatory approvals.